[TNF-alpha inhibitors].
Fain
Olivier
O
Service de médecine interne, hôpital Jean Verdier (AP-HP), université Paris Nord, Bondy. olivier.fain@jvr.ap-hop-paris.fr
D020083:Acquired Hyperostosis Syndrome / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001528:Behcet Syndrome / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D015337:Multicenter Studies as Topic; D010919:Placebos; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D012507:Sarcoidosis / Q000188:drug therapy; D012859:Sjogren's Syndrome / Q000188:drug therapy; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014657:Vasculitis / Q000188:drug therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D010919:Placebos; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept